Nanoblade technology: high efficiency delivery of crisprs components in primary cells by virus like particles.

The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Keywords: CRISPR, Cas9, Virology, Gene editing, Gene therapy

Patent Application number: null

Inventors:

null

Publications:

Efficient genome editing in primary cells and in vivo using viral-derived ’Nanoblades’ loaded with Cas9/sgRNA ribonucleoproteins https://www.biorxiv.org/content/early/2017/10/12/202010

Reference:

BIO15247-T1

Elodie Acloque
Business Developer

Phone

E-mail

Patent filling date: 20-10-2015

Rare disease: No

Second indication: No

Nanoblade technology: high efficiency delivery of crisprs components in primary cells by virus like particles.

You might also be interested in